{"id":71505,"date":"2026-05-20T10:30:00","date_gmt":"2026-05-20T10:30:00","guid":{"rendered":"https:\/\/medsbase.com\/vip-vasoactive-intestinal-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"vip-vasoactive-intestinal-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/vip-vasoactive-intestinal-peptide\/","title":{"rendered":"VIP (Vazoaktivn\u00ed intestin\u00e1ln\u00ed peptid) \u2014 v\u00fdzkumn\u00e1 kvalita"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je VIP (Vazoaktivn\u00ed intestin\u00e1ln\u00ed peptid)?<\/h3>\n

VIP<\/strong> (Vazoaktivn\u00ed intestin\u00e1ln\u00ed peptid; CAS 40077-57-4, MW 3,325.79 g\/mol) je syntetick\u00fd 28-aminokyselinov\u00fd neuropeptid identick\u00fd s p\u0159irozen\u00fdm lidsk\u00fdm VIP. Sekvence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2<\/sub> (C-termin\u00e1ln\u00ed amid). \u010clen VIP\/PACAP \/ sekretin-glukagonov\u00e9 superrodiny<\/strong>. VIP p\u016fsob\u00ed na VPAC1 a VPAC2 receptory<\/strong> (Gs-v\u00e1zan\u00e9 GPCR) a vyvol\u00e1v\u00e1 \u0161irokou \u0161k\u00e1lu fyziologick\u00fdch \u00fa\u010dink\u016f: vazodilataci, relaxaci st\u0159evn\u00ed hladk\u00e9 svaloviny, exokrinn\u00ed sekreci, modulaci neurotransmiter\u016f, regulaci sp\u00e1nku\/cirkadi\u00e1nn\u00edho rytmu a \u0161irokou protiz\u00e1n\u011btlivou \/ imunomodula\u010dn\u00ed aktivitu<\/strong>. Publikovan\u00fd v\u00fdzkum se zam\u011b\u0159uje na roli VIP v Th2-polarizovan\u00e9 imunomodulaci, farmakologii autoimunitn\u00edch onemocn\u011bn\u00ed (modely RA, MS, IBD) a neuroprotekci. Pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd VIP \u226599% HPLC ov\u011b\u0159en\u00fd \u00b7 COA dostupn\u00fd na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 dod\u00e1vka pro v\u00fdzkum \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
T\u0159\u00edda slou\u010denin<\/strong><\/td>\nSyntetick\u00fd 28-aa neuropeptid; agonista receptor\u016f VPAC1\/VPAC2; \u010dlen nad\u0159azen\u00e9 rodiny sekretinu-glukagonu<\/td>\n<\/tr>\n
CAS \u010d\u00edslo<\/strong><\/td>\n40077-57-4 (lidsk\u00fd VIP)<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2<\/sub> (HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2<\/sub>; 3,325.79 g\/mol<\/td>\n<\/tr>\n
item7<\/strong><\/td>\nS; mol\u00e1rn\u00ed hmotnost 3326.78 g\/mol (28-aa voln\u00e1 amidov\u00e1 skupina).<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nC147<\/sub>H237<\/sub>N43<\/sub>O43<\/sub>S; MW 3326.78 g\/mol (28-aa voln\u00fd amid neuropeptid).<\/td>\n<\/tr>\n
Mechanismus \u00fa\u010dinku<\/strong><\/td>\nVPAC1 (\u0161irok\u00e9 rozlo\u017een\u00ed: pl\u00edce, gastrointestin\u00e1ln\u00ed trakt, T bu\u0148ky, mozek, j\u00e1tra) a<\/strong> (\u0161irok\u00e1 distribuce: pl\u00edce, GIT, T-lymfocyty, mozek, j\u00e1tra) a (hladk\u00e9 svaly, mastocyty, CNS) s podobnou afinitou (n\u00edzk\u00e9 nM K<\/strong> (hladk\u00e9 svalstvo, \u017e\u00edrn\u00e9 bu\u0148ky, CNS) s podobnou afinitou (n\u00edzk\u00e1 nM KD<\/sub>Lyofilizovan\u00fd b\u00edl\u00fd a\u017e b\u011blav\u00fd pr\u00e1\u0161ek, \u226599% HPLC. Skladujte p\u0159i 2\u20138 \u00b0C kr\u00e1tkodob\u011b, p\u0159i \u221220 \u00b0C dlouhodob\u011b (\u226536 m\u011bs\u00edc\u016f). Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. Pro laboratorn\u00ed v\u00fdzkum pouze. Nen\u00ed na zak\u00e1zan\u00e9m seznamu WADA. Aviptadil (syntetick\u00e1 formulace VIP) byla inhala\u010dn\u00ed cesta ve f\u00e1zi III v\u00fdzkumu pro COVID-19 ARDS, ale nez\u00edskala regula\u010dn\u00ed schv\u00e1len\u00ed.<\/td>\n<\/tr>\n
Forma \/ \u010cistota \/ Skladov\u00e1n\u00ed<\/strong><\/td>\nPro laboratorn\u00ed v\u00fdzkum pouze. Nen\u00ed na zak\u00e1zan\u00e9m seznamu WADA. Aviptadil (syntetick\u00e1 formulace VIP) m\u011bla inhala\u010dn\u00ed cestu ve f\u00e1zi III v\u00fdzkumu pro COVID-19 ARDS, ale nez\u00edskala regula\u010dn\u00ed schv\u00e1len\u00ed.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed na Seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA. Aviptadil (syntetick\u00e1 formulace VIP) pro\u0161el inhala\u010dn\u00edm v\u00fdzkumem f\u00e1ze III u COVID-19 ARDS, ale nez\u00edskal regula\u010dn\u00ed schv\u00e1len\u00ed.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 VPAC1 \/ VPAC2 farmakologie<\/h2>\n